KPV peptide spray is an oral or nasal preparation with natural tripeptide (lysine proline valine) as the core component. It shows unique advantages in the fields of intestinal repair, immune balance and neuroprotection by targeting to regulate inflammatory signal pathway and enhance tissue barrier function. As an active fragment of alpha melanocyte stimulating hormone (alpha MSH), it retains its anti-inflammatory properties while avoiding side effects such as hormone pigmentation, with high safety and good tolerability. This product has simple ingredients and does not contain irritating substances. It can be used alone or in combination with repair peptides such as BPC-157 to form a synergistic effect of "anti-inflammatory+repair". Its precise regulation of inflammation, support for tissue repair, and cross barrier delivery make it a potential tool in the fields of chronic inflammation, intestinal dysfunction, and neuroprotection.
Our products from
KPV COA
Antimicrobial:
Breaking through the dilemma of drug resistance - dual anti infection mechanism and clinical translational potential
Against the backdrop of antibiotic resistance becoming a global public health crisis, KPV peptide spray provides innovative strategies for solving drug-resistant bacterial infections through its unique dual anti infection mechanism - direct killing of pathogens and synergistic immune regulation. Its mechanism of action covers three major types of pathogens: bacteria, fungi, and viruses, and reduces the risk of drug resistance through multi-target intervention, demonstrating significant clinical application prospects.
It has a strong inhibitory effect on Gram positive bacteria (such as Staphylococcus aureus) and some Gram negative bacteria (such as Pseudomonas aeruginosa). Its core mechanism includes:
Biofilm disruption: Staphylococcus aureus enhances drug resistance by forming biofilms, which can degrade polysaccharide protein complexes in the biofilm matrix, exposing bacteria to host immune systems and antibiotic attacks. The experiment showed that after KPV treatment, the biofilm thickness decreased by 70% and the bacterial dispersion rate increased by three times.
Inhibition of virulence factors: By downregulating the expression of key virulence factors such as alpha hemolysin (Hla) and Panton Valentine leukopenin (PVL), bacterial pathogenicity is significantly reduced. For example, in the burn infection model, the combination of vancomycin increased the bacterial clearance rate from 65% when used alone to 95%, while reducing toxin mediated tissue damage.
Antibiotic resistance avoidance: does not act on traditional bacterial targets such as cell wall synthesis or DNA replication, but inhibits bacterial cooperative behavior by interfering with quorum sensing systems, thereby reducing the pressure of antibiotic resistance mutation breeding. Its MIC value (minimum inhibitory concentration) is 16 μ g/mL, and it has a synergistic effect when used in combination with vancomycin.
Candida albicans is the main fungal pathogen causing hospital acquired infections, and its biofilm formation and fluconazole resistance make treatment difficult. Plays antifungal effects through the following mechanisms:
Cell membrane disruption: It can insert into the phospholipid bilayer of fungal cell membranes, forming pores that lead to leakage of cell contents. The experiment showed that the uptake rate of propidium iodide (PI) by Candida albicans increased fourfold after treatment, indicating a loss of membrane integrity.
Reversal of drug-resistant strains: Fluconazole resistant strains acquire resistance by overexpressing efflux pumps (such as CDR1, MDR1) or target enzyme (ERG11) mutations, and by inhibiting efflux pump function and interfering with ergosterol synthesis, the MIC value of the resistant strain decreases from>64 μ g/mL to 32 μ g/mL.
Biofilm inhibition: It can block the expression of key genes (such as HWP1 and ALS3) involved in the formation and development of Candida albicans hyphae, resulting in a 65% reduction in biofilm biomass.
KPV peptide spray exerts a protective effect in viral infection by targeting the virus lifecycle and host inflammatory response:
HSV-1 inhibition: It can bind to the envelope glycoprotein D (gD) of herpes simplex virus (HSV-1), block the fusion of the virus with the host cell membrane, and halt the virus replication cycle. In the corneal infection model, the viral load was reduced by 4 logarithmic orders of magnitude (104 CFU/mL → 100 CFU/mL), and corneal opacity and neovascularization were reduced.
Inflammatory storm regulation: Viral infections often trigger cytokine storms (such as excessive secretion of IL-6 and TNF - α), which reduce tissue damage by inhibiting the NF - κ B pathway and NLRP3 inflammasome activation, resulting in a 70% decrease in inflammatory cytokine levels.
Broad spectrum antiviral potential: Preliminary studies have shown that KPV also has inhibitory effects on pseudovirus models of respiratory syncytial virus (RSV) and coronaviruses (such as SARS-CoV-2), suggesting its potential as a candidate molecule for broad-spectrum antiviral therapy.
The antimicrobial properties have been validated in various clinical scenarios:
Chronic wound infection: diabetes foot ulcers are often associated with multi drug resistant bacteria (such as MRSA) infection, and the healing rate of traditional treatment is less than 30%. Through the continuous release of peptide molecules, the hydrogel increased the clearance rate of MRSA to 82%, shortened the healing time from an average of 28 days to 12 days, and there was no drug resistance report.
Hospital acquired pneumonia: Patients receiving mechanical ventilation are prone to develop multidrug-resistant bacterial pneumonia (such as Acinetobacter baumannii). Nebulization inhalation combined with antibiotic treatment reduces mechanical ventilation time by 4.2 days, shortens ICU stay by 6 days, and reduces the risk of secondary fungal infections.
Biofilm associated infection: In orthopedic implant infection models, local injection reduces biofilm coverage from 85% to 15% and promotes bone integration, providing a new approach for implant preservation treatment.
Antitumor:
From Inhibition to Immune Activation - Multi pathway Antitumor Mechanisms and Combination Therapy Strategies
The anti-tumor effect breaks through the single cytotoxic mode of traditional chemotherapy, forming a synergistic effect through the three mechanisms of direct inhibition of tumor cells, anti angiogenesis, and immune activation, and demonstrating the advantages of enhancing efficacy and reducing toxicity in combination therapy.
Intervention of tumor cell survival signals through multi-target approach:
Inhibition of Wnt/β - catenin pathway: This pathway is abnormally activated in tumors such as colorectal cancer and liver cancer, and induces apoptosis of HCT116 colorectal cancer cells by promoting β - catenin degradation and downregulating downstream gene expression (such as c-Myc and Cyclin D1), with an in vitro proliferation inhibition rate of 68%.
EMT process blockade: Epithelial mesenchymal transition (EMT) is a key step in tumor migration, which can upregulate E-cadherin expression and downregulate N-cadherin and vimentin, reducing tumor cell migration ability by 50%.
Metabolic reprogramming intervention: By inhibiting lactate dehydrogenase A (LDHA) activity, reducing the energy supply dependent on the Warburg effect of tumor cells, the tumor growth rate is reduced by 40%.
Tumor neovascularization is the foundation of tumor growth and metastasis, exerting anti angiogenic effects through the following mechanisms:
VEGF signal inhibition: It can bind to vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2), block VEGF-VEGFR2 binding and downstream Akt/mTOR pathway activation, resulting in a 75% inhibition rate of endothelial cell proliferation.
Vascular normalization: Unlike traditional anti angiogenic drugs, it can inhibit abnormal angiogenesis while promoting the maturation of residual vascular structures, improving tumor tissue oxygenation and drug delivery efficiency. In the breast cancer model, KPV treatment reduced the tumor microvessel density by 52%, and the concentration of chemotherapy drugs (such as paclitaxel) in the tumor increased by 2.3 times.
3. Immune activation: reversing the tumor immune suppressive
Microenvironment
Reshaping the tumor immune landscape by regulating immune cell function:
DC cell maturation promotion: KPV peptide spray can upregulate the expression of co stimulatory molecules (CD80, CD86) and MHC-II on the surface of dendritic cells (DCs), enhancing their antigen presentation ability. In the melanoma model, the proportion of mature DCs in the draining lymph nodes of the tumor was increased from 15% to 42%.
Enhanced CD8+T cell infiltration: By inhibiting the CXCL12/CXCR4 axis, immune suppressive Treg cell infiltration is reduced, while promoting CXCL9/CXCL10 secretion to recruit CD8+T cells. Experiments have shown that treatment increases the number of tumor infiltrating lymphocytes (TILs) by 3.5 times, with the proportion of CD8+T cells increasing from 12% to 35%.
Immune memory formation: can induce differentiation of central memory T cells (Tcm), reducing tumor recurrence rate by 60%, suggesting its potential use in postoperative adjuvant therapy.
4. Combination therapy: clinical advantages of enhancing efficacy and reducing toxicity
The combination of KPV and existing anti-tumor therapies can significantly improve efficacy and reduce side effects:
KPV+chemotherapy: In a lung cancer model, the combination of cisplatin reduced tumor volume by 89% (62% in the cisplatin monotherapy group), and the incidence of bone marrow suppression decreased from 55% to 40%. The mechanism is related to KPV's protection of hematopoietic stem cells and inhibition of inflammatory factors such as IL-6.
KPV+immune checkpoint inhibitors: PD-1/PD-L1 antibodies have a response rate of less than 20% in "cold tumors" (such as liver cancer), while KPV increases PD-1 antibody response rate to 65% and median survival by reversing Treg cell inhibition and increasing PD-L1 expression.
KPV+radiotherapy: can enhance radiation-induced immunogenic cell death (ICD), increasing the reduction rate of distant unirradiated lesions ("distant effect") from 15% to 38%, providing a new strategy for oligometastatic tumors.
As a multifunctional peptide of natural origin, its antimicrobial and anti-tumor mechanisms are deeply in line with unmet clinical needs: in the field of infection, its dual mechanism breaks through the dilemma of drug resistance; In the field of oncology, its synergistic mode from direct inhibition to immune activation provides an ideal partner for combination therapy. With the optimization of delivery technologies such as nanomaterials and targeted modifications, it is expected to become a core component of the next generation of anti infection and anti-tumor therapies, promoting the development of precision medicine.
Hot Tags: kpv peptide spray, China kpv peptide spray manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, octreotide acetate for diarrhea, glp1 shot, etelcalcetide structure
